We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $193M
1-Year Est. Return 208.51%
This Fund
S&P 500
This Quarter Est. Return
+33.89%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$165M
AUM Growth
+$30.6M
Cap. Flow
+$8.38M
Cap. Flow %
5.07%
Top 10 Hldgs %
37.21%
Holding
97
New
34
Increased
10
Reduced
12
Closed
29

Top Buys

Rank Stock Value
1
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$9.28M
2
NBP
NovaBridge Biosciences American Depositary Shares
NBP
+$4.89M
3
APGE icon
Apogee Therapeutics
APGE
+$3.6M
4
CVS icon
CVS Health
CVS
+$2.99M
5
AKRO
Akero Therapeutics
AKRO
+$2.84M

Top Sells

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$2.99M
2
FULC icon
Fulcrum Therapeutics
FULC
+$2.5M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$2.49M
4
VSTM icon
Verastem
VSTM
+$2.49M
5
GERN icon
Geron
GERN
+$2.07M

Sector Composition

Rank Sector Weight
1 Healthcare 89.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MBX
51
MBX Biosciences
MBX
$3.14B
$917K 0.56%
52,402
-10,674
-17% -$143K
FULC icon
52
Fulcrum Therapeutics
FULC
$273M
$909K 0.55%
98,799
-346,150
-78% -$2.5M
MBX
53
PUT
MBX Biosciences
MBX
$3.14B
$884K 0.54%
+50,500
New +$675K
COGT icon
54
CALL
Cogent Biosciences
COGT
$6.65B
$646K 0.39%
+45,000
New +$533K
CNTA
55
PUT
DELISTED
Centessa Pharmaceuticals
CNTA
$606K 0.37%
+25,000
New +$444K
ESTA icon
56
Establishment Labs
ESTA
$2.72B
$537K 0.33%
13,100
– –
PRAX icon
57
CALL
Praxis Precision Medicines
PRAX
$8.58B
$530K 0.32%
+10,000
New +$485K
MBX
58
CALL
MBX Biosciences
MBX
$3.14B
$525K 0.32%
+30,000
New +$401K
ACAD icon
59
PUT
Acadia Pharmaceuticals
ACAD
$4.43B
$427K 0.26%
+20,000
New +$473K
ABUS icon
60
Arbutus Biopharma
ABUS
$857M
$343K 0.21%
75,484
– –
PGEN icon
61
PUT
Precigen
PGEN
$2.24B
$329K 0.2%
+100,000
New +$282K
KPTI icon
62
PUT
Karyopharm Therapeutics
KPTI
$43.5M
$315K 0.19%
+48,100
New +$259K
REPL icon
63
Replimune Group
REPL
$941M
$308K 0.19%
73,614
-324,232
-81% -$2.07M
VTYX
64
DELISTED
Ventyx Biosciences
VTYX
$188K 0.11%
+60,600
New +$161K
IMUX icon
65
Immunic
IMUX
$190M
$153K 0.09%
+17,390
New +$153K
ATYR
66
CALL
aTyr Pharma
ATYR
$47.6M
$28.8K 0.02%
+40,000
New +$181K
ACAD icon
67
CALL
Acadia Pharmaceuticals
ACAD
$4.43B
– –
-93,222
Closed -$2.01M
AKRO
68
PUT
DELISTED
Akero Therapeutics
AKRO
– –
-58,579
Closed -$3.13M
ALT icon
69
PUT
Altimmune
ALT
$552M
– –
-107,000
Closed -$414K
ALVO icon
70
Alvotech
ALVO
$1.39B
– –
-78,372
Closed -$715K
ANAB icon
71
AnaptysBio
ANAB
$1.58B
– –
-15,000
Closed -$333K
APLS
72
DELISTED
Apellis Pharmaceuticals
APLS
– –
-98,600
Closed -$1.71M
AZN icon
73
PUT
AstraZeneca
AZN
$263B
– –
-14,181
Closed -$3.93M
BCRX icon
74
BioCryst Pharmaceuticals
BCRX
$2.28B
– –
-172,883
Closed -$1.55M
CLDX icon
75
Celldex Therapeutics
CLDX
$2.99B
– –
-73,000
Closed -$1.49M
1 2
3
4

Similar funds

WWC
Waypoint Wealth Counsel Atlanta, Georgia $193M AUM 30.17% 1-Year Est. Return
JHA
Jackson Hill Advisors Houston, Texas $193M AUM 4.94% 1-Year Est. Return
TDWM
Topel & Distasi Wealth Management Berkeley, California $193M AUM 12.07% 1-Year Est. Return
DF
Downshift Financial Boulder, Colorado $193M AUM
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
PA
Promethium Advisors Bethesda, Maryland $193M AUM 23.69% 1-Year Est. Return
SCPM
Sea Cliff Partners Management San Francisco, California $194M AUM 8.22% 1-Year Est. Return
CA
Carson Advisory Athens, Georgia $193M AUM 14.52% 1-Year Est. Return

Exome Asset Management's Q3 2025 Portfolio in Review

As of Q3 2025, Exome Asset Management held 97 positions worth $165M, up 23% from $135M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Exome Asset Management deployed $8.38M of net new capital in Q3 2025, opening 34 new positions and adding to 10 existing holdings. Its largest new stake was MoonLake Immunotherapeutics: 178,084 shares worth $1.28M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 80% a quarter earlier.

On the sell side, the largest reduction was Fulcrum Therapeutics, an estimated $2.5M trimmed.

  • Exome Asset Management's largest Q3 2025 buy was MoonLake Immunotherapeutics: 178,084 shares worth $1.28M.
  • Exome Asset Management added most to Eli Lilly in Q3 2025, an estimated $2.37M increase.
  • Exome Asset Management's biggest Q3 2025 reduction was Fulcrum Therapeutics, cutting an estimated $2.5M.
  • Exome Asset Management fully exited Scholar Rock in Q3 2025, selling an estimated $2.99M.
  • Exome Asset Management's ten largest holdings make up 37% of its $165M portfolio in Q3 2025.
  • Exome Asset Management opened 34 new positions and closed 29 in Q3 2025.
  • Exome Asset Management's portfolio value rose 23% quarter-over-quarter to $165M.

Based on Exome Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.